Regina Gálvez-López ¹ , Marta Rodríguez-Camacho ¹ , Andrés Soriano-Mateos ¹ , Eloi Querol-Carranza ¹
1 Estudiante del Máster en Neurociencias Básicas Aplicadas y Dolor de la Universidad de Granada (UGR)

Julia Cervilla-Carrión
² , Andrea Martín-Manzano ² , María Luisa Martín-Vázquez ² , Cristina de-la-Torre-Sánchez ² , Carolina Sobrino-Cano ² , Rocío Soto-García ²
2 Student of the BA in Translation and Interpreting at the University of Granada (UGR)

Neuropathic pain (NP) is a difficult-to-manage kind of pain that affects 10% of the population. Nowadays, there are some agents that can be used for its treatment, and they are grouped according to different lines. However, their pharmacological effectiveness is only proved on a reduced number of patients. For this reason, new therapeutic strategies need to be developed. Certain molecules currently are on the initial stages of human clinical trials, and many of them are showing encouraging results. Furthermore, there is an increasingly accurate knowledge about the different molecular pathways related to NP. This advance is promoting the development of new molecules with potential therapeutic targets. Some of these agents are being tested with animal models, and they are showing a significant analgesic potency. Finally, non-pharmacological treatment in NP is becoming more important in clinical practice through alternatives such as radio frequency, stimulation, and nerve block therapy. The aim of this work is to review the state of art of NP treatment. For that purpose, the agents approved until today and their main action mechanisms should be considered, with a special emphasis on some of the latest molecules used on human clinical
trials and those which are in development with animal models. Moreover, some of the main non-pharmacological strategies used to manage pain nowadays are also reviewed.
Keywords: neuropathic pain, new agents, pharmacological treatment, non-pharmacological treatment, clinical trial.